A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer
Stopped early · Phase 2
Conditions studied: Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Invasive Breast Cancer
In brief
This research study is designed to look at the effects of the combination of vorinostat (Suberoylanilide Hydroxamic Acid or Zolinza) and tamoxifen on breast cancer tissue. The investigators will do this by comparing tissues from the original breast biopsy to tissues obtained after taking vorinostat and tamoxifen for 2 weeks.
Key facts
- Study ID
- NCT01194427
- Run by
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- People needed
- 2
- Starts
- 2011-03-01
- Expected to finish
- 2011-11-01
- Last updated by the study team
- 2013-05-17
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Stage I-III invasive breast cancer
- Awaiting surgery or neoadjuvant treatment
- ECOG performance status 0, 1 or 2
- Adequate organ function
- Prior use of hormone contraception or replacement therapy must have been discontinued at least 30 days prior to diagnostic biopsy (unless participant is willing to undergo an additional biopsy for the study)
You may not qualify if…
- Prior or current treatment of any kind for the current breast cancer
- Current use of any other investigational drugs
- Uncontrolled or active infection, congestive heart failure, cardiac arrythmia, or psychiatric illness
Where it is running
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.